Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL)

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL) trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 2 trials

RecruitingPhase 1

NCT06173518

A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic…

This is a Phase 1b/2 study to evaluate the safety and efficacy of autologous T cells engineered with a chimeric antigen receptor (CAR) targeting cluster of diff…

United States, Spain30 participantsStarted 2023-11-16

Treatment: AUTO1

RecruitingPhase 1

NCT06393738

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

This clinical trial is studying the safety and potential anti-tumor activity of an investigational drug called ARV-393 in patients diagnosed with advanced Relap…

United States255 participantsStarted 2024-09-05

Treatment: ARV-393, Glofitamab

All recent trials (3 shown)

CompletedPhase 2

NCT03610724

Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients

The purpose of the study was to assess the efficacy and safety of tisagenlecleucel in pediatric, adolescent and young adult patients with relapsed/refractory B-…

United States34 participantsStarted 2019-02-15

Treatment: Tisagenlecleucel, lymphodepleting chemotherapy